Cancer survivor rates are tragic stories of those who did not survive are
invoked on both sides of the health care debate? Does reform promise to
treat the untreated or will it threaten new and exciting technologies.
Dr. Nicholas Vogelzang now directs research for U.S. Oncology - the parent company of the Comprehensive Cancer Centers of Nevada and he previously
headed the Nevada Cancer Institute. Vogelzang gives us his take on how
cancer treatment fits into the reform debate.